ARDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Faruqi & Faruqi, LLP is reminding investors of Ardelyx (NASDAQ: ARDX) about an upcoming deadline for a securities class action lawsuit on November 16, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding the commercial performance and growth prospects of its drugs XPHOZAH and IBSRELA, failing to disclose increasing payer-related access and reimbursement barriers. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, and suffered losses may be eligible to participate.
Class Action Alert: Levi & Korsinsky Reminds Ardelyx, Inc. (ARDX) Investors of November 16, 2026 Deadline
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding the commercial performance and growth prospects of XPHOZAH and IBSRELA, concealing issues related to payer access and reimbursement. This led to a significant stock price drop on August 7, 2026, after Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH guidance.
Is Ardelyx (ARDX) Undervalued Following Its PM360 Trailblazer Awards?
Ardelyx (ARDX) recently received several PM360 Trailblazer Awards, including recognition for its CEO and IBSRELA marketing team, bringing attention to its stock performance. Despite a recent share price decline, the company boasts a strong 5-year total shareholder return and trades at a significant discount to analyst targets. The article explores whether the market is accurately pricing the risks or underestimating Ardelyx's potential, given its growing addressable markets and improving sales strategies.
ARDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ardelyx, Inc. Securities Lawsuit - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased ARDX securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx misrepresented its commercial strategy and revenue outlook for IBSRELA and XPHOZAH, leading to an 18% stock price decline after the company reduced its 2026 revenue guidance. Investors with significant losses are encouraged to contact Levi & Korsinsky to potentially lead the class action and oversee the litigation.
ARDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Faruqi & Faruqi, LLP is reminding investors of Ardelyx (ARDX) about a securities class action lawsuit deadline on November 16, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding the commercial performance of its drugs, XPHOZAH and IBSRELA, failing to disclose increasing payer-related access and reimbursement barriers. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, and suffered losses are encouraged to contact the firm.
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
SueWallSt is reminding investors of Ardelyx, Inc. (ARDX) about a securities class action lawsuit with a lead plaintiff deadline of November 16, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding its revenue outlook and long-term growth prospects for its drugs IBSRELA and XPHOZAH, while failing to disclose increasing access barriers due to payer utilization-management processes. This alleged misinformation led to a significant stock price decline when guidance was eventually cut and withdrawn on August 6, 2026.
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
SueWallSt is reminding investors of Ardelyx, Inc. (ARDX) about a securities class action lawsuit deadline. Investors have until November 16, 2026, to take action. The article provides a headline only, indicating no further details about the lawsuit are present in this specific news item.
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
SueWallSt is reminding investors of Ardelyx, Inc. (NASDAQ: ARDX) about a securities class action lawsuit with a lead plaintiff deadline of November 16, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding its revenue outlook and long-term growth prospects for IBSRELA and XPHOZAH, while allegedly concealing increasing payer-related access and reimbursement barriers. The stock price reportedly declined by 18% after the company reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance.
A podcast on gut disorders wins gold at the PM360 awards
Ardelyx (ARDX) received multiple honors at the 2026 PM360 Trailblazer Awards, recognizing its chief executive, Mike Raab, as Life Sciences Manufacturer CEO of the Year. The company's podcast, "Gut Matters: Discoveries and Innovations," won Gold in the Podcast Initiative category, and the IBSRELA Marketing Team secured the Silver Marketing Team of the Year award. These accolades highlight Ardelyx's leadership, innovative patient engagement, and strategic marketing in the biopharmaceutical industry.
Securities Lawsuit Alert: Ardelyx, Inc. (ARDX) Investors - Contact Levi & Korsinsky Before November 16, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who suffered losses due to alleged securities fraud between January 13, 2025, and August 6, 2026. The lawsuit claims Ardelyx made misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, while concealing issues like increasing payer access restrictions. Investors are encouraged to contact Levi & Korsinsky before November 16, 2026, to explore potential recovery.
ARDX UPCOMING DEADLINE: Levi & Korsinsky Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has alerted stockholders of Ardelyx, Inc. (NASDAQ: ARDX) about a pending securities class action lawsuit. The lawsuit alleges that Ardelyx made misleading statements about its patient-access strategy, which purportedly failed to disclose stringent prior authorization requirements impacting new-patient starts for IBSRELA and XPHOZAH. Investors who purchased shares between January 13, 2025, and August 6, 2026, and suffered losses are encouraged to contact the firm, with a lead plaintiff deadline set for November 16, 2026.
Lost Money on Ardelyx, Inc. (ARDX)? Join Class Action Before November 16, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of investors who suffered losses due to alleged securities fraud between January 13, 2025, and August 6, 2026. The lawsuit claims Ardelyx made misleading statements about its commercial performance and growth prospects for XPHOZAH and IBSRELA, concealing issues with payer access and reimbursement. The stock price declined by approximately 18% after the company reduced its IBSRELA revenue guidance and withdrew its long-term XPHOZAH guidance on August 6, 2026.
Debt to equity ratio of Ardelyx, Inc. – HAN:41X
This article displays the debt to equity ratio for Ardelyx, Inc. (HAN:41X) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The data is provided by ICE Data Services and FactSet Research Systems Inc.
Operating cash flow per share of Ardelyx, Inc. – HAN:41X
The article focuses on the operating cash flow per share of Ardelyx, Inc., traded under the ticker HAN:41X on the Hannover Stock Exchange. It provides a financial overview and indicates that the market is currently closed with no trades. The content appears to be an excerpt from a financial data platform, highlighting company financials.
Class Action Lawsuit Filed: Ardelyx, Inc. (ARDX) - Join by November 16, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, particularly concerning patient access and reimbursement barriers. This led to a significant stock price decline on August 7, 2026, after the company reduced revenue guidance and withdrew long-term guidance due to these issues.
Lost Money on Ardelyx, Inc. (ARDX)? Contact Levi & Korsinsky to Join Class Action Before November 16, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of investors who suffered losses due to alleged securities fraud between January 13, 2025, and August 6, 2026. The lawsuit claims Ardelyx made false and misleading statements regarding the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, concealing issues with patient access and reimbursement. This led to a significant stock price decline after the company reduced and withdrew revenue guidance on August 6, 2026.
Class Action Lawsuit Filed Against Ardelyx, Inc. (ARDX) - Recover Losses - Contact Levi & Korsinsky Before November 16, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of investors who suffered losses due to alleged securities fraud between January 13, 2025, and August 6, 2026. The lawsuit claims Ardelyx made misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, while concealing issues like increasing payer-related access barriers. This led to a significant stock price decline after Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH guidance on August 6, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements by failing to disclose increasing payer-related access and reimbursement barriers for its drugs, XPHOZAH and IBSRELA, which negatively impacted commercial performance. Investors have until November 16, 2026, to request to be appointed as lead plaintiff.
Ardelyx Inc Lobbyists, 2025
This OpenSecrets article details Ardelyx Inc.'s lobbying activities and lobbyists for the year 2025. It lists 25 named lobbyists, with 13 (52%) having prior federal government experience (revolving door). The article breaks down the lobbyists by the firms they represent and provides a comprehensive roster, indicating which lobbyists are ex-government or in-house.
ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misrepresentations regarding payer utilization management and prescription pull-through, which allegedly slowed new-patient starts for IBSRELA, while the company reaffirmed its 2025 sales guidance. Investors have until November 16, 2026, to file a motion for lead plaintiff.
Investor Alert: Deadline Approaching to Join Ardelyx, Inc. (ARDX) Class Action - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements regarding its commercial performance and growth prospects for XPHOZAH and IBSRELA, particularly concerning payer-related access barriers. Investors who suffered losses are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Rosen Law Firm is encouraging investors of Ardelyx, Inc. (NASDAQ: ARDX) who purchased common stock between January 13, 2025, and August 6, 2026, to secure counsel before the November 16, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Ardelyx made misleading statements about the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, concealing issues like increasing payer-related access and reimbursement barriers. Investors who suffered damages are urged to join the class action to seek compensation.
Investors in Ardelyx, Inc. (ARDX): Protect Your Rights - Contact Levi & Korsinsky Before November 16, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, concealing issues like increasing payer access barriers. This came to light on August 6, 2026, when Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew its XPHOZAH long-term revenue guidance, leading to an 18% stock price drop.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc.
The Rosen Law Firm is encouraging investors of Ardelyx, Inc. (NASDAQ: ARDX) to join a class action lawsuit filed on behalf of those who purchased common stock between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, concealing issues like increasing payer access barriers and stringent prior authorization requirements. Investors wishing to serve as lead plaintiff must do so by November 16, 2026.
November 16, 2026 Deadline Approaching: Join Class Action Against Ardelyx, Inc. (ARDX) - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for investors who suffered losses between January 13, 2025, and August 6, 2026. The lawsuit alleges Ardelyx made misleading statements about its commercial performance and growth prospects, particularly concerning challenges with XPHOZAH and IBSRELA. The firm is encouraging affected shareholders to join the class action before the November 16, 2026, deadline.
Kaplan Fox Encourages Investors of Ardelyx, Inc. (NASDAQ: ARDX) to Contact the Firm to Learn About Their Legal Rights
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased common stock between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding its commercial performance and growth prospects for IBSRELA and XPHOZAH, particularly concerning increased payer utilization-management processes that impacted patient access and slowed new-patient starts. Investors who suffered losses are encouraged to contact Kaplan Fox, with a lead plaintiff deadline of November 16, 2026.
ARDX Class Action Reminder - Robbins LLP Reminds Investors
Robbins LLP is reminding investors that a class action lawsuit has been filed against Ardelyx, Inc. (NASDAQ: ARDX). The lawsuit alleges that Ardelyx misled investors about the commercial performance and growth prospects of its drug products, IBSRELA and XPHOZAH, leading to a significant stock drop on August 6, 2026. Investors who purchased ARDX common stock between January 13, 2025, and August 6, 2026, are encouraged to contact Robbins LLP before the November 16, 2026, lead plaintiff deadline.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made false or misleading statements regarding increasing payer-related access and reimbursement barriers affecting its products XPHOZAH and IBSRELA, negatively impacting commercial performance and growth prospects. Investors are encouraged to join the case by November 16, 2026, to request lead plaintiff status.
Levi & Korsinsky Urges Ardelyx, Inc. (ARDX) Shareholders to Act Before Lead Plaintiff Deadline November 16, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements about the commercial performance of its drugs XPHOZAH and IBSRELA, concealing issues like increasing payer access barriers. This led to a significant stock price drop on August 7, 2026, after the company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
Pomerantz LLP has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who suffered losses. The lawsuit alleges securities fraud, stemming from Ardelyx's reduced 2026 IBSRELA revenue guidance and withdrawal of XPHOZAH revenue guidance, which led to a significant stock price drop. Investors have until November 16, 2026, to apply to be lead plaintiff.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
SueWallSt is notifying shareholders of Ardelyx, Inc. (NASDAQ: ARDX) about a securities class action lawsuit against the company, specifically naming Chief Commercial Officer Eric Foster as a defendant. The lawsuit alleges that Foster made misleading statements regarding patient access to the company's drugs IBSRELA and XPHOZAH, while payer restrictions were actually hindering prescriptions. Investors who purchased ARDX securities between January 13, 2025, and August 6, 2026, and suffered losses, have until November 16, 2026, to apply for lead plaintiff status.
Portnoy Law Firm Announces Class Action on Behalf of Ardelyx, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. Investors are encouraged to contact the firm by November 16, 2026, to file a lead plaintiff motion and discuss legal options. The lawsuit alleges Section 10(b) and Section 20(a) violations, citing various instances of alleged corporate wrongdoing and misleading representations by executives.
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDX
Levi & Korsinsky, LLP is reminding investors of Ardelyx, Inc. (NASDAQ: ARDX) about a pending class action lawsuit with a lead plaintiff deadline of November 16, 2026. The lawsuit alleges that Ardelyx executives made misleading statements regarding sales projections for XPHOZAH and IBSRELA while concealing payer access issues. The complaint names four Ardelyx officers individually, citing their control over public statements and SEC filings.
Did You Lose Money on Ardelyx, Inc. (ARDX)? Levi & Korsinsky Urges Investors to Act Before November 16, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of investors who suffered losses due to alleged securities fraud between January 13, 2025, and August 6, 2026. The lawsuit claims Ardelyx made misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, and concealed increasing payer-related access barriers. This led to a significant stock price drop after the company reduced its revenue guidance in August 2026.
Uncovering Potential: Penny Stocks To Watch In September 2026
This article highlights several penny stocks—Ardelyx (ARDX), MediciNova (MNOV), and Grab Holdings (GRAB)—that show potential for growth in September 2026, despite the inherent risks associated with such investments. It details their financial health, operational summaries, recent performance, and future outlooks. The piece emphasizes that while the U.S. market exhibits positive momentum, investors should focus on companies with strong financial foundations when considering penny stocks.
Ardelyx, Inc. (ARDX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 16, 2026 Deadline
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Ardelyx, Inc. on behalf of investors who purchased securities and suffered losses between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, concealing issues like increasing payer-related access and reimbursement barriers. The firm is reminding investors of the November 16, 2026, deadline to seek recovery in this case.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc.
Rosen Law Firm is encouraging investors of Ardelyx, Inc. (NASDAQ: ARDX) to secure legal counsel before the November 16, 2026, deadline to serve as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its products XPHOZAH and IBSRELA, concealing issues like increasing payer-related access barriers. Investors who purchased Ardelyx common stock between January 13, 2025, and August 6, 2026, may be entitled to compensation.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) and some of its officers, alleging violations of federal securities laws. The lawsuit claims that Ardelyx made misleading statements and failed to disclose increasing payer-related access and reimbursement barriers affecting patient access to their drugs, XPHOZAH and IBSRELA. Investors who purchased Ardelyx securities between January 13, 2025, and August 6, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 16, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased securities between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx made misleading statements by failing to disclose increasing payer-related access and reimbursement barriers impacting patient access to its drugs XPHOZAH and IBSRELA, which negatively affected the company's commercial performance. Investors who suffered losses are encouraged to join the case by November 16, 2026, as the firm operates on a contingency fee basis.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP is reminding investors of Ardelyx, Inc. (NASDAQ: ARDX) about a class action lawsuit alleging securities fraud. The lawsuit claims Ardelyx made misleading statements regarding reimbursement barriers affecting patient access to its products, XPHOZAH and IBSRELA, which impacted the company's commercial performance. Shareholders who purchased ARDX shares between January 13, 2025, and August 6, 2026, are encouraged to contact the firm by the November 16, 2026 deadline to discuss their rights.
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased common stock between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx misled investors about the commercial performance and growth prospects of its products, XPHOZAH and IBSRELA, by concealing issues related to payer access and reimbursement. Stockholders with significant losses are encouraged to contact the firm by November 16, 2026, to potentially serve as lead plaintiff.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
The Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Ardelyx, Inc. common stock between January 13, 2026, and August 6, 2026. Investors who bought shares during this period have until November 16, 2026, to move the court to serve as lead plaintiff. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, particularly concerning patient access and reimbursement barriers.
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Ardelyx expects to generate nearly $500 million in revenue this year and achieve profitability by 2027, driven by its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH. The company has revised its IBSRELA revenue guidance due to payer pressures but still believes in a $1 billion peak revenue opportunity, albeit taking longer to reach. Ardelyx is also expanding its pharmacy network and studying IBSRELA for chronic idiopathic constipation while focusing XPHOZAH's commercial efforts on Medicaid and commercially insured patients outside the Medicare bundle.
Class action lawsuit filed against Ardelyx over misleading statements on drug sales and patient access.
A class action lawsuit has been filed against Ardelyx on behalf of investors who purchased stock between January and August 2026. The lawsuit alleges that Ardelyx made false statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, specifically citing issues with payer access and patient reimbursement. Investors who bought Ardelyx stock during this period are encouraged to join the lawsuit by November 16, 2026.
Investor Alert: Robbins LLP Informs Investors of the Ardelyx, Inc. Class Action Lawsuit
Robbins LLP has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who purchased common stock between January 13, 2025, and August 6, 2026. The lawsuit alleges that Ardelyx misled investors about the commercial performance and growth prospects of its drug products, IBSRELA and XPHOZAH. Ardelyx's stock dropped significantly on August 6, 2026, after the company reduced its IBSRELA revenue guidance and withdrew XPHOZAH's long-term revenue guidance, citing increased payer utilization-management processes and "evolving market dynamics."
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Ardelyx, Inc. (ARDX) Investors of November 16, 2026 Deadline
Levi & Korsinsky, LLP has announced a securities class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) with a deadline of November 16, 2026, for investors. The lawsuit alleges that Ardelyx made misleading statements regarding the commercial performance and growth prospects of its drugs, XPHOZAH and IBSRELA, concealing issues with patient access and prior authorization. This came to light on August 6, 2026, when Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH guidance, leading to an 18% stock price drop.
Ardelyx at cantor global healthcare conference: growth meets payer pressure
Ardelyx presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting its path to profitability by 2027 despite increasing payer pressure on its IBSRELA and XPHOZAH products. The company detailed strategies to mitigate reimbursement challenges, protect its intellectual property, and explore pipeline expansion while maintaining confidence in its long-term financial targets. Ardelyx aims for profitability through strong product economics and disciplined capital allocation, including potential opportunistic acquisitions.
Ardelyx CHRO James Brady sells $58,378 in stock By Investing.com
James Parker Brady, the Chief Human Resources Officer at Ardelyx (NASDAQ:ARDX), sold 15,136 shares of company stock for a total of $58,378. These sales were automatically executed to cover withholding taxes related to restricted stock unit awards. The transaction occurs while ARDX stock is trading near its 52-week low and follows recent news of increased Q2 revenue but also revised guidance and a drop in stock price.
Ardelyx CHRO James Brady sells $58,378 in stock
Ardelyx CHRO James Brady sold 15,136 shares of company stock worth $58,378 on August 21, 2026, primarily to cover tax withholdings from restricted stock unit awards. This sale occurred while ARDX stock traded near its 52-week low, despite analysts maintaining a strong buy consensus and the stock appearing undervalued. The transaction follows recent company news of increased second-quarter revenue but revised guidance for its IBSRELA product and withdrawn revenue targets for XPHOZAH, leading to a stock price drop and a surge in options trading.
Ardelyx chief patient officer sells $41,419 in stock By Investing.com
Laura A. Williams, Chief Patient Officer at Ardelyx, Inc. (NASDAQ:ARDX), sold 10,739 shares of company stock for $41,419 on August 21, 2026, to cover withholding taxes from RSU vesting. This transaction occurred while ARDX shares are near their 52-week low, despite analysts maintaining a "Strong Buy" consensus and InvestingPro suggesting the stock is undervalued. The sale follows Ardelyx's recent Q2 revenue increase and revised guidance for its products, which has led to increased investor interest and options trading activity.
